Navigation Links
Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures
Date:7/23/2014

t program has involved over 3,000 people and offers over eight years of clinical experience with some patients.1 We look forward to discussing the data with the regulatory authorities and the scientific community."

Based on the results of the brivaracetam Phase 3 program, UCB plans to submit a New Drug Application to the US Food & Drug Administration (FDA) and a Marketing Authorization Application to the European Medicines Agency (EMA) in early 2015.

This Phase 3 study was a randomized, double-blind, placebo-controlled, multicentre, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam (100 and 200 mg/day) compared to placebo, over a 12-week treatment period, in 768 randomized focal epilepsy patients (aged 16 to 80 years) with partial-onset seizures, not fully controlled despite treatment with one or two concomitant AEDs.2,7 The primary endpoint for the European regulatory authorities is the 50% responder rate for partial-onset seizure frequency compared with placebo, over the treatment period standardized to a 28-day duration. The primary endpoint for the FDA is the percent reduction over placebo for partial-onset seizure frequency, over the treatment period standardized to a 28-day duration.2 Detailed data from this study will be submitted for presentation at upcoming epilepsy congresses and for publications in peer-reviewed journals.

About brivaracetam and the Phase 3 clinical development program Discovered and developed by UCB, brivaracetam is a highly selective synaptic vesicle protein 2A ligand.8,9

The phase 3 clinical development plan for brivaracetam consisted of the following studies:N01252: an evaluation of the efficacy and safety/tolerability of adjunctive brivaracetam 20, 50, and 100 mg/day compared with placebo over 12 weeks, in 399 randomized patients (greater than or equal to 16 to 70 yea
'/>"/>

SOURCE UCB
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Majority of Biotech/Pharma Employees Poised to Job Hunt
2. ZenCash Plucks Top Executives from Major DFW Brands
3. Accelerated Cure Project for Multiple Sclerosis Approved for Major Funding Award from Patient-Centered Outcomes Research Institute to Create MS Patient-Powered Research Network
4. Clinovo Rolls Out Major Enhancements for Open Source EDC ClinCapture at Outsourcing in Clinical Trials West Coast Conference
5. Verified Clinical Trials Stops Dual Enrollment in Clinical Trials in Major CNS Clinical Trials to Reduce Potential Adverse Events and Improve Data Quality
6. Major CRO Gives Top Ratings To Verified Clinical Trials To Stop Dual Enrollment In Clinical Trials On Late Phase Trial
7. Kibow Biotech Achieves Major Victory with Indias IPAB Decision to Uphold 2009 Product Patent
8. Sales Momentum Introduces 5 Payoffs to Asking Questions in Sales Calls in a White Paper - Mastering Major Account Selling
9. Dyadic International To Present At Two Major Conferences In December 2013
10. Sales Momentum Shares Three Common Pitfalls to Avoid When Developing Major Account Sales Strategies
11. The Blazing Diamond and the Quantum Jewel: Two Major Discoveries in Quick Succession
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... IDIX ) announced today that it will report,its ... Tuesday, November 6,2007 after the U.S. financial markets close. ... release, Idenix,management will host a conference call at 4:30 ... company,s financial results for the third quarter,2007. To ...
... 31 Modigene Inc. (OTC,Bulletin Board: MODG) today announced ... & Renshaw 9th Annual Healthcare Conference on,Wednesday, November 7, ... held at,the New York Palace Hotel in New York ... Novik will attend.,Management will provide a company overview and ...
... DIEGO, Oct. 31 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ... Acumen,BioFin(TM) Rodman & Renshaw 9th Annual Healthcare Conference on ... PST). The conference is being,held at the New York ... Executive Officer of Anadys,Pharmaceuticals, Inc. will present an overview ...
Cached Biology Technology:Modigene to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference 2
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
... scientific institutions today announced the launch of the Encyclopedia ... 1.8 million named species of animals, plants, and other ... time in the history of the planet, scientists, students, ... living species, even those that have just been discovered. ...
... that could revolutionize manufacturing for certain materials, researchers have ... world. While still slightly less than 2 centimeters long, ... , The fibers--which have the potential to be longer, ... many other materials--could ultimately find use in smart fabrics, ...
... study examines the use of tissue-engineered scaffolding made of ... naturally, to replace defective cartilage tissue. Cartilage cells are ... into the body, where new cartilage tissue is grown ... Artificial Organs. , The procedure was extremely successful in ...
Cached Biology News:World's leading scientists announce creation of 'Encyclopedia of Life' 2World's leading scientists announce creation of 'Encyclopedia of Life' 3World's leading scientists announce creation of 'Encyclopedia of Life' 4The longest carbon nanotubes you've ever seen 2
... cassette is designed to allow ampicillin selection ... gb2 driving the gene for ampicillin resistance ... Em7 promoter. It mediates higher transcription efficiency ... synthetic polyadenylation signal terminates the ampicillin expression. ...
... cassette is designed to allow ampicillin ... promoter gb2 driving the gene for ampicillin ... the Em7 promoter. It mediates higher transcription ... A synthetic polyadenylation signal terminates the ampicillin ...
... is designed for the fast and simple ... at any position (for the generation of ... is designed to allow neomycin / kanamycin ... combines a prokaryotic promoter (gb2) for expression ...
... Pyronin Y is most widely used ... selectively and differentially stain nucleic acids ... dichromatic dye solution, Pyronin Y stains ... DNA green. Chem comp: ...
Biology Products: